Skip to main content
. 2014 Sep 9;74(5):1029–1032. doi: 10.1007/s00280-014-2580-z

Fig. 1.

Fig. 1

Leucovorin (LV) may abrogate pralatrexate (PDX) activity through three mechanisms. i Competition for reduced folate carrier type 1 (RFC) transport into cell. ii Competition for polyglutamylation, a retention and activity marker, by folylpolyglutamate synthase (FPGS). iii Provides an alternate source of tetrahydrofolate, working around PDX inhibition of dihydrofolate reductase (DHFR)